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doi:10.1016/j.jtcvs.2003.12.024TObjective: End-stage heart failure has been associated with high mortality in the
absence of transplantation. We evaluated the outcome of patients receiving optimal
medical therapy who were removed from the cardiac transplant waiting list to
determine survival and predictors of mortality.
Methods: We performed a retrospective review of 27 patients removed from the
cardiac transplant waiting list from 1999 to 2001 at our institution.
Results: Mean age was 53  11 years; 16 of the patients were male. Status was
IB in 3 cases and II in 24. Median time on the list was 32 months, and median
follow-up was 2.9 years. Patients were removed from the transplant list because
of either clinical improvement (group A, n  18) or deterioration (group B, n 
9). In group A, 13 patients had improved functional status and 10 were in New
York Heart Association class 1 or 2; 16 had improved echocardiographic left
ventricular function. Survivals at 3 years were 100% in group A and 44% in
group B (P  .01).
Conclusion: Patients with end-stage heart failure who have clinical response to
medical therapy have excellent 3-year survival. These data suggest the necessity of
close evaluation of patients waiting for transplantation, with a low threshold for
inactivation if persistent clinical improvement is observed.
Patients with end-stage heart failure continue to have a poor progno-sis.1-2 Cardiac transplantation has been shown to have a greatersurvival benefit than conventional medical treatment, as well as thepossibility of return to preillness activity levels.3 This observation isless clear-cut with recent advances in multimodal therapy, which havebeen associated with dramatic improvements in the end points of
mortality and hospital admissions.4,5 A study stratifying patients according to Heart
Failure Survival Score showed that only those at highest risk of dying had a
mortality risk reduction with transplantation.6 Other observational studies have
concluded that candidates surviving longer than 6 months on the waiting list should
7,8be considered too well for transplantation.
he Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 5 1481
Cardiothoracic Transplantation Shah et al
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status and need for transplantation should be reassessed
periodically. However, there are no data available on the
short- and long-term survivals of patients who have been
removed from the United Network for Organ Sharing
(UNOS) registry. We sought to evaluate the outcomes of
these patients to determine overall survival and predictors of
mortality.
Methods
The study was a retrospective review of the clinical records of
patients who were removed from the heart transplant waiting list
between August 1, 1999, and July 31, 2001. Patients were initially
registered between September 1993 and November 2000. Data
from the transplant database were supplemented from the clinical
files of each patient. In the case of missing variables, inpatient
medical records were reviewed. The study was approved by the
institutional review board of the Washington University School of
Medicine.
Clinically relevant variables included age, sex, diagnosis, list-
ing status at time of registration, and reason for transplant list
inactivation. New York Heart Association (NYHA) functional
class and left ventricular function as assessed by echocardiography
were noted both at listing and at inactivation. Current cardiovas-
cular medications were recorded, as was any use of inotropic
therapy or surgical intervention such as pacemaker or automatic
implantable cardiac defibrillator (AICD). Patients’ treatment reg-
imens were based on published guidelines of tailored optimal
medical therapy.9,10
Patients were followed up until August 1, 2002. Information
regarding survival or the circumstances of death was obtained
from the chart review or from the referring physician assigned to
the patient’s care. No patients were unavailable for follow-up.
All data were entered into an Excel spreadsheet (Microsoft
Corporation, Redmond, Wash). Differences between population
subgroups were analyzed by Pearson 2 test for nominal variables.
Kaplan-Meier survival curves were constructed from the patient
cohort and for specific combinations of dichotomous characteris-
tics. Statistical analysis and Kaplan-Meier survival curves were
calculated with SYSTAT software (Systat Software, Inc, Point
Richmond, Calif).
Results
A total of 27 patients included in this study were divided
TABLE 1. Clinical status of group B patients
Progressive renal dysfunction
Refused transplant due to age
Peripheral vascular disease
Worsening chronic obstructive pulmonary disease
Obesity with dietary noncompliance
Age-related renal dysfunction
Pulmonary hypertension
Renal insufficiency with pulmonary hypertension
Renal insufficiency with cerebrovascular accidentinto two groups. Group A (n  18) consisted of patients
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by the evaluating cardiologist, was classified as clinical
improvement with medical therapy. Group B (n  9) con-
sisted of patients who were removed because of advancing
age (n  2) or clinical deterioration (n  7), making them
unsuitable candidates for transplantation (Table 1).
With respect to clinical characteristics, group B patients
were older, more likely to be male, and likely to have
ischemic cardiomyopathy (Table 2). There was no differ-
ence in functional status according to NYHA class or left
ventricular function by echocardiography at listing.
At the time of removal from the waiting list, 13 group A
patients (72%) had improved NYHA functional status, and
10 (55%) were in NYHA functional class I or II (mean class
2.28  0.8). Echocardiographic left ventricular function
improved in 16 patients (88%, mean 2.56  0.8). Alto-
gether, all 18 group A patients showed improvement: 2 by
NYHA functional status only, 5 by echocardiography, and
11 by both. Among group B patients, only 3 (33%) had
improvement in NYHA functional class, and 2 (22%) had
deterioration (mean class 3.33  0.5). There were no
changes in left ventricular function in this group.
Of all patients, 85% were receiving angiotensin convert-
ing enzyme inhibitors, 89% were receiving digoxin, and
93% were receiving furosemide. There was no difference in
medical treatment between the two patient cohorts. In ad-
dition, 3 patients were in status IB with a need for inotropic
therapy, 2 patients had implanted pacemakers, and 10 had
AICDs.
During the follow-up period, survival was better in group
A (Table 3). Overall, 6 patients in group B had died at the
time of follow-up, with 4 deaths occurring in the first year
TABLE 2. Clinical characteristics at listing
Characteristic
Group A
(n  18)
Group B
(n  9) P value
Age (y, mean  SD) 48.7 10 61.4 6 .01
Sex (male/female ratio) 8:10 8:1 .04
Cause of heart failure (No.) .07
Idiopathic 15 4
Ischemic 3 5
Listing status (No.) .25
IB 1 2
II 17 7
NYHA class (mean  SD) 3.17 0.7 3.44 0.7 .26
Left ventricular function by
echocardiography* (mean
 SD)
3.89 0.3 3.89 0.3 .99
Inotropic support (No.) 1 2 .25
Permanent pacemaker (No.) 1 1 .60
AICD (No.) 6 4 .57
*Left ventricular function classified as follows: 1, Normal; 2, mild dysfunc-
tion; 3, moderate dysfunction; 4, severe dysfunction.after removal from the waiting list. None of the patients in
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1). Status IB and need for inotropic therapy as an isolated,
dichotomous variable also predicted a worse survival (Fig-
ure 2). Survivals at 1 and 3 years were 66.7% and 33.3% for
status IB and 100% and 92% for status II (P .01). Patients
with dilated cardiomyopathy also had improved survival
relative to those with ischemic cardiomyopathy (Figure 3).
Discussion
In this limited retrospective study we sought to determine
the survival of patients who were listed for heart transplan-
tation and subsequently removed. Given the natural history
of end-stage heart failure, the survival of these patients was
expected to be dismal. Interestingly, of the subgroup of
patients who had improvement with medical therapy, all
were alive at a median follow-up of 3.7 years. Our data
suggest that patients in status II, particularly those with
dilated cardiomyopathy, have a favorable survival if clinical
improvement is observed. These results are remarkable
when contrasted with the high mortality expected according
to the Framingham study.1
Improved survival is probably related to advances in the
multimodal pharmacotherapy of heart failure. Although the
number of patients in this study was small to evaluate the
impact of implantable devices, it is also likely that the
widespread use of AICDs and resynchronization therapy
has further improved survival.11,12 This study also high-
Figure 1. Freedom from death during follow-up. Freedom from
death was significantly higher in group A than in group B (log-
rank method). Follow-up began at time of initial listing on trans-
plant registry (P < .05).lights the current imperfect science of predicting an indi-
The Journal of Thoracicvidual patient’s response to medical therapy. The patients
listed for heart transplantation were all judged to have
end-stage heart failure, and all medical treatments had been
optimized before their listing. Nevertheless, a subgroup
showed clinical improvement during the wait for an allo-
graft. This improvement was to such a degree that removal
of these patients from the transplant list was warranted, with
continued excellent survival. These data confirm the need
for constant reevaluation of UNOS-listed patients.7,8
The modern era of medical and surgical treatment of
TABLE 3. Outcome and follow-up
Event
Group A
(n  18)
Group B
(n  9)
Death on waiting list (No.) 0 6
Congestive heart failure 0 4
Nonembolic colonic ischemia 0 1
Pulmonary arterial rupture
during right heart
catheterization
0 1
Total follow-up* (y, median and
range)
6.2 (2.0-8.9) 2.9 (0.7-4.8)
Time spent on the waiting list
(y, median and range)
3.7 (0.1-7.8) 2.3 (0.6-3.7)
*Follow-up began at time of registration.
Figure 2. Freedom from death by listing status. Freedom from
death was significantly higher in status II than status I patients
(log-rank method). Follow-up began at time of initial listing on
transplant registry (P < .05).heart failure has offered many new therapies that have
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failure admissions.4,5 In fact with optimal medical treatment
and device therapy, such as biventricular pacing and
AICDs, there has been a considerable change in mortality
among patients in end-stage heart failure awaiting cardiac
transplantation,11,12 even those receiving inotropic support
at home.13 Surgical options have also expanded, including
high-risk coronary revascularization, mitral valve repair,
ventricular remodeling, and use of marginal cardiac do-
nors.14-18 Unfortunately, despite these efforts, the organ
donor shortage is a real problem, because the number of
cardiac transplantations seems to have reached a plateau.
Solutions to address this problem need to be devised to
approach the equilibrium point between organ supply and
demand.
In successive analyses of the UNOS database through the
years, there has been a consistent improvement in survival
of transplant recipients as a result of improvements in
postoperative care and immunosuppression. Unfortunately,
the shortage of donor hearts continues to be a major limiting
factor in offering this lifesaving operation to all those wait-
ing on the transplant list. The 2002 UNOS Annual Report
listed the number of patients awaiting hearts to be approx-
imately 3700, with an additional 3154 patients added and
only 2141 undergoing transplantation.19
To address methods for improving organ supply, in a
Figure 3. Freedom from death by etiology of cardiomyopathy.
Freedom from death was significantly higher in patients with
dilated cardiomyopathy than in those with ischemic cardiomyop-
athy (log-rank method). Follow-up began at time of initial listing
on transplant registry (P < .05).recent survey of the transplant medical community consist-
1484 The Journal of Thoracic and Cardiovascular Surgery ● Maing of members of the International Society of Heart and
Lung Transplantation and the Foundation for Advancement
of Cardiac Therapies, 75% of the respondents supported
presumed consent, and 70% supported indirect compensa-
tion (eg, payment of funeral expenses and charity dona-
tions).20 In addition, a large number thought that consulta-
tion with next of kin should not be obtained if a donor card
had been signed. These provocative issues will likely be the
subject of much debate as these matters are further ex-
panded and legislative consideration is given to them.
Kao and colleagues,8 in an evaluation of patients who
were on the heart transplant list for 6 months or more,
reported no survival benefit relative to patients undergoing
transplantation within 6 months. The recognized limitation
of that study was that most of these patients had continued
clinical deterioration and required inotropic support, a con-
dition known to be associated with high mortality.21 Our
study clearly differs in that most patients were removed
from the transplant list because of clinical improvement.
Among other controversies regarding strategies aimed at
optimizing outcome, Deng and colleagues22 have suggested
the need for revising the current system of organ allocation.
In particular, recent improvements in medical and surgical
therapies question the survival benefit conferred by heart
transplantation on patients in stable condition. Is it perhaps
time to conduct a well-designed, prospective randomized
trail to assess this notion?
This review is limited by its retrospective nature. As
such, certain variables could not be assessed. Although
AICDs and biventricular pacemakers have improved out-
comes for patients, we could not address this in our study.
Functional status and quality of life were not assessed in our
cases, although other studies have shown that similar pa-
tients who are in stable condition on medical therapy show
exercise capacity and self-assessed quality of life similar to
those of patients who have undergone transplantation.23,24
In conclusion, this study suggests that a continued re-
evaluation of patients on the heart transplant list as UNOS
status II is warranted. For patients demonstrating clinical
improvement, removal from the transplant list and contin-
ued medical management seems prudent in terms of overall
survival. If a patient’s condition deteriorates at any time,
relisting remains an option. For patients who are inotrope
dependent, cardiac transplantation remains the criterion
standard treatment. Ultimately, the benefit of cardiac trans-
plantation in stable status II patients may need to be deter-
mined by a well-planned and orchestrated prospective tri-
al.20
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